| pubmed-article:19319531 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C1332717 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C1706438 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C0034790 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C0085358 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C0040690 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C1413244 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C2698600 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C1426807 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:19319531 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:19319531 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19319531 | pubmed:dateCreated | 2009-8-19 | lld:pubmed |
| pubmed-article:19319531 | pubmed:abstractText | This study demonstrates that CD8+ T cells in the tumor microenvironment display reduced functionality and hyporesponsiveness. TGF-beta contributed markedly to the tumor-infiltrating CD8+ T cells' (TILs) reduced functionality, which could be reversed using a small molecule TGF-beta inhibitor. Upon T-cell receptor (TCR) activation, the activation of ITK and ERK kinases were reduced in CD8+ TILs, as compared to splenic CD8+ T cells: TGF-beta inhibitor could reverse this phenomenon. This study demonstrates for the first time the association of the Spred-1 gene, an inhibitor of the Ras/MAPK pathway, with CD8+ TILs and TGF-beta activity. Spred-1 was upregulated in CD8+ TILs and TGF-beta enhanced the expression of Spred-1 in effector/memory CD8+ T cells and not in rested/memory CD8+ T cells. Based on these findings, this study supports the hypothesis that TGF-beta mediates an inhibitory mechanism on CD8+ TILs involving TCR-signaling blockade and the upregulation of Spred-1, thus implicating Spred-1 as a potential new target for future anti-tumor immune studies. | lld:pubmed |
| pubmed-article:19319531 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19319531 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19319531 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19319531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19319531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19319531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19319531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19319531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19319531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19319531 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19319531 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19319531 | pubmed:issn | 1432-0851 | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:WakefieldLala... | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:SchlomJeffrey... | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:TakaiShinjiS | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:SabzevariHele... | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:LutsiakM E... | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:SemnaniRoshan... | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:MostböckSvenS | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:di... | lld:pubmed |
| pubmed-article:19319531 | pubmed:author | pubmed-author:FarsaciBenede... | lld:pubmed |
| pubmed-article:19319531 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19319531 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:19319531 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19319531 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19319531 | pubmed:pagination | 1809-18 | lld:pubmed |
| pubmed-article:19319531 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:meshHeading | pubmed-meshheading:19319531... | lld:pubmed |
| pubmed-article:19319531 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19319531 | pubmed:articleTitle | TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. | lld:pubmed |
| pubmed-article:19319531 | pubmed:affiliation | Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, MSC 1750, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:19319531 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19319531 | pubmed:publicationType | Research Support, N.I.H., Intramural | lld:pubmed |
| entrez-gene:21803 | entrezgene:pubmed | pubmed-article:19319531 | lld:entrezgene |
| entrez-gene:114715 | entrezgene:pubmed | pubmed-article:19319531 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19319531 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19319531 | lld:entrezgene |
